***Curriculum Vitae*, Iris Lindberg, Ph.D.**

**Date**: January 15, 2012

**Contact Information:**

Address:     Department of Anatomy and Neurobiology

University of Maryland-Baltimore

20 Penn St, HSFII, S251

Phone:  (410) 706 4778 (office) or  -4787 (lab)

Fax: (410) 706 2512

E-mail:  [ilind001@umaryland.edu](mailto:ilind001@umaryland.edu)  *or* ilindb@yahoo.com

Website: thelindberglab.com

**Education**

        1975 A.B.  Biochemistry University of California at Berkeley

        1980 Ph.D. Pharmacology   Univ. of Wisconsin-Madison Medical School

**Post-Graduate Education and Training**

   1981 ‐ 1984     Staff Fellow, NRSA Postdoctoral Fellow

                           and Pharmacology Research Associate Trainee (PRAT program)

                                     Laboratory of Preclinical Pharmacology,

NIMH, St. Elizabeth’s Hospital, Washington D.C.

**Employment**

        1984 ‐ 1989     Assistant Professor, Dept. of Biochemistry and Molecular Biology

Louisiana State University Medical School

New Orleans, LA

1989 ‐ 1994     Associate Professor (tenured), Dept. of Biochemistry and Molecular Biology,

Louisiana State University Health Sciences Center (name changed)

New Orleans, LA

        1994 ‐ 2007   Professor, Dept. of Biochemistry and Molecular Biology

Louisiana State University Health Sciences Center

New Orleans, LA

2006 - 2007 LSUHSC Cancer Center Member

2007 - present Professor, Department of Anatomy and Neurobiology

University of Maryland Medical School

Baltimore, MD

Secondary Appointment: Department of Biochemistry

Member, Greenebaum Cancer Center

**Professional Society Memberships**

1978 ‐ present Society for Neuroscience

1982-present Winter Conference on Brain Research

1985 ‐ 2005; 2011-pres. American Society for Biochemistry and Molecular Biology

1999 ‐2005 American Society for Cell Biology

2001 ‐ present The Endocrine Society

**Career Development Awards and Honors**

1981 NIH Individual Postdoctoral Fellowship (switched to PRAT)

1981‐1983 Pharmacology Research Associate Traineeship (PRAT)

1988‐1993 Research Career Development Award (NIDDK)

1993‐1998 Research Scientist Development Award (NIDA)

1998‐2003 Research Scientist Development Award (NIDA)

**Administrative Service**

***Institutional Service (Committees)***

1985-present Neuroscience Center Executive Steering Committee

1986-1988 Biochemistry Dept. Graduate Recruitment Committee

1992-1997 LSUHSC Graduate Council

1996-2000 LSUHSC Neuroscience Center Faculty Recruitment Committee

1997-2002 Neuroscience Center Graduate Program Recruitment Committee

2001 LSU School of Medicine Research Retreat Committee

2003-2004 Emergency Preparedness Faculty Committee, LSUHSC

2003-2005 LSUHSC Research Council

2004 Biochemistry Dept. Graduate Recruitment Committee

2004-2005 Faculty Search Committee, Biochemistry Department

2004-2005 Graduate Advisor, Biochemistry Department

2004-2005 LSUHSC Graduate Council

2005-2007 Faculty Assembly, LSUHSC

2007- present Program in Neuroscience Seminar Committee, University of Maryland

2007- present Program in Neuroscience Training Committee, University of Maryland

2007- present Dept. Anatomy & Neurobiology Promotions Committee;

**Chair, 2010- present**

2008- present Dept. Anatomy & Neurobiology Faculty Search Committee

2008- 2011 Proteomics Core Steering Committee, University of Maryland

2009- present Radiation Safety Institutional Committee, University of Maryland

2009- 2010 Pharmacology Head Search Committee, University of Maryland

2009- present Departmental Representative to School of Medicine Council

2009- present **Organizer**, Departmental “Second Monday” Work-in-Progress seminar series

2010, 2012 Qualifying Exam Committee, Program in Neuroscience

2010- present **Chair,** Program in Neuroscience Retreat Committee

2011 Univ. of Maryland Strategic Plan Subcommittee (Research)

2012- present Univ. of Maryland Program in Neurosciences Postdoctoral Training Grant Steering Committee

***Other Institutional Service***

1990, 1992, 1995, 1997 LSUHSC Design & production of Biochemistry Dept. recruitment brochure

1997-2002 LSUHSC Neuroscience Center brochure production

2004- 2006 LSUHSC Grantsmanship presentations to faculty and students

2008 Presentation to UMB grad students: “How to Succeed in Grad School”

2010 “Getting an RSDA” (Wendy Sanders’ Professional Skills program)

2010-present Junior faculty mentoring committees, Drs. Elizabeth Powell, Andree Lessard, and Marta Lipinski

***Ph.D. Thesis Committees***

**Louisiana State University Health Sciences Center:** Minetta Gardinier, Jeremy Springhorn, Richard Shen, Yi Zhou, John Mathis,  Tamim Shaikh,

Erik Pakarinen, Joomyeong Kim, Virginia Strand, Astrid Roy, Ping Wei, Mary Breslin,

Neva West, Yolanda Fortenberry, Mike Serou,  Changning Gong, Bin Tu, Peimin Zhu,

Yuri Peterson, Faramarz Taheri, Elly Park, and Tanya Roy

**University of Maryland-Baltimore**:

Amanda Elson, Zhongping Liu, Akina Hoshino, Adam Clark, and Erik Martin

***Other Service***

1985‐86, 1988‐89 *Secretary,* Greater New Orleans Society for Neuroscience

2005‐2006 *President,* Greater New Orleans Society for Neuroscience

In 2005-06, my major duty was to organize the distribution of

$100,000 in Katrina relief funds from the national Society for Neuroscience to local neuroscience graduate students.

2008-2011 Winter Conference on Brain Research, Scientific Board

2012-2013 President, Greater Baltimore Society for Neuroscience

***National Service***

***Ad hoc* and regular grant reviewer:**

1987 Study section reviewer, NLS1

1989, 1997 Study section reviewer, NIDA Biochemistry

1989, 1990 Special emphasis panel member, NIDDK

1990- present *Ad hoc* reviewer, *J. Biol. Chem., J. Neurochem., Peptides, J. Neurosci., Analyt. Biochem., FEBS Lett., Protein Eng., Design and Selection,* *Proc. Natl Acad Sci, Endocrine Rev., Diabetes, Molecular Medicine and Metabolism, Mol. Cell. Endocrinol., J. Endocrinol., PLoS ONE,* and others

1991 Study section reviewer, NIMH career awards

1994 Special emphasis panel member, NINDS

1995 Study section reviewer, NLS1

1995, 1996, 1998 Study section and special emphasis panel reviewer, NIDDK

1996, 1997, 2002 Study section reviewer (phone reviews), NLS1

1996-2000 **Regular member, Endocrinology study section**

1998, 2000 Advisory Committee Member, Gordon Conference: *Hormonal and Neural Peptide Synthesis*

1999 Study section reviewer, ACS

2000-2005 **Editorial Board Member, *Journal of Biological Chemistry***

2000 NIMH Career Awards study section reviewer

2000-2005 Endocrinology study section  reviewer ( about 1 panel per year)

2002 Vice‐Chair, Gordon Conference:*Hormonal and Neural Peptide Synthesis*

2004 Chair, Gordon Conference: *Proprotein Processing, Trafficking, and  Secretion*

2006-2010 Advisory Committee Member, Gordon Conference: *Proprotein Processing, Trafficking, and Secretion*

* 1. **Regular member, Molecular and Cellular Endocrinology study section**

2010 Special Emphasis Panel reviewer, NIDDK 2/2010

2011 *EUREKA* NIH review panel member

2012-2017 **Editorial Board Member, *Journal of Biological Chemistry***

***International Review Service***

2002 Finnish National Academy of Sciences Review Panel, Helsinki, Finland

2002, 2009 Canada Research Chairs, College of Reviewers, applicant reviewer

2003 Chair, Finnish National Academy of Sciences Review Panel

2005 Foundation for Scientific Research‐ Flanders, Belgium, grant reviewer

2006 Wellcome Trust grant reviewer

2008-2010 Foundation for Scientific Research‐ Flanders, Belgium, grant reviewer

2011 Medical Research Council (U.K.), grant reviewer

***Teaching Service***

1985‐ 1986   Dental Biochemistry (17 lecture h per year) - 85 students

1985‐2005  One lecture in “Methods in Neuroscience”  - 15 students

(course given at Tulane University in alternate years

on protein expression methods) (2 h)

1987 ‐1999   Medical Biochemistry (17 h) -150 students

1991, fall   Graduate seminar in the cell biology of protein targeting (20 h) 8 students

1995 ‐ 2001  Neuroscience Survey (2 h) 8 students

1997   Endocrinology (on radioimmunoassay and opioid peptides) (2 h) 10 students

1998‐ 2004   Molecular Neuroscience (on neurotransmitters) (4 h) 8 students

2000   Nursing Biochemistry (20 h) 80 students

2001 Graduate Seminar in Protein Motifs (20 h) 7 students

2001, 2002   Special Topics Graduate Seminar in Methods in Biochemistry;

(Protein Expression and Purification) (2 h); 8 students

2003, 2005   Endocrinology - Bioactive peptides and radioimmunoassay (4 h and 2h); 12 students

2003‐2005 Graduate Seminar-    “Professional Skills”.

Graduate student mentoring: giving talks, preparing grants,

manuscripts, career choices (30 h); 12 students

2006  Dental Biochemistry (4 h); 85 students

2006  Molecular Neuroscience ‐ Neuropeptides (4 h) and Grantsmanship (1 h)

2006, 2007  Endocrinology Graduate course   “Radioimmunoassay and other

hormone‐measurement techniques” (2 h); 25 students (included Allied Heath

students)

2008- present (**UMB)** Professional Skills course in Molecular Medicine “How to Write/Review Grants” (1 h) ; 20 students

2008- present GPILS Core Course “Posttranslational Processing” (1 h); 50 students

2009- present Ethics Class, Discussion Leader (1.5 h) twice a year (small group of 6-8)

2010 -present Neuroscience (GPILS 641) “Peptides, Modulators and Growth Factors” (1 1/2 h);

10-12 students

2010- present Structure and Development “Endocrine Systems” (1 h); 180 students

**Students and postdoctoral fellows supervised**

***Graduate Students supervised  (rotation students not listed)***

1. Fu‐sheng Shen (1986‐ 1988) (Ph.D. 1990, from Institute of Physiology, Beijing)

2. John Mathis (1988‐ 1994) Ph.D. 1994

3. Yi Zhou (1990‐ 1994) Ph.D. 1994

4. Yolanda Fortenberry (1997‐ 2001) Ph.D. 2001

5. Maria Sayah (3/00‐ 12/00) (Master’s thesis; French practical training)

6. Valery Iattignon (1/04‐ 4/04) (Master’s thesis; French practical training)

7. Akina Hoshino (11/07- 4/2012)

***Postdoctoral Fellows supervised***

1.  Dr. Nympha B. DʹSouza (1987‐1988)

2. Dr. Steven F. Roberts (1988‐ 1991)

3.  Dr. Joseph Irvine (1989‐ 1991)

4. Dr. Fu‐sheng Shen (1991‐ 1992)

5.  Dr. Osvaldo Vindrola (1991‐ 1993)

6. Dr. Nazarius Lamango (1994‐ 1996)

7. Dr. Xiaorong Zhu (1994‐ 1997) (NRSA fellow)

8. Dr. Karla Johanning (1994‐ 1998)

9.  Dr. Laurent Muller (1996‐ 1999)

10. Dr. Ekaterina Apletalina (1997‐ 2000)

11. Dr. Jae‐Ryoung Hwang (1998‐ 2001)

12. Dr. Angus Cameron (1999‐ 2000)

13. Dr. Virginie Laurent (1999‐2002)

14. Dr. Ashok Dubey (2000‐ 2001)

15. Dr. Miroslav Sarac (2000‐ 2003)

16. Dr. Emmanuel Prodhomme (2001‐2002)

17. Dr. Weidong Liu (2001‐2002)

18. Dr. Sang‐Nam Lee (2002‐ 2007)

19. Dr. Juan Ramon Peinado (2003‐2004)

20. Dr. Magdalena Kacprzak (2003‐ 2005)

21. Dr. Bainan Liu (2004‐ 2005)

22. Dr. Dorota Kowalska (2005) and (2008-2009)

23. Dr. Wagner Judice (2006- 2007) (NIDA INVEST Fellow)

24. Dr. Jin Liu (2006‐ 2008)

25. Dr. Akihiko Ozawa (2006‐ 2011)

26. Dr. Michael Helwig (2009- 2012) (supported by Leopoldina Fellowship)

27. Dr. Mirella Vivoli (2010- 2012)

28. Dr. Indrani Dasgupta (2011-2013)

29. Dr. Laura Sanglas (2011-2012) (supported by Danish Academy Fellowship)

30. Dr. Elias Blanco (2013- present)

**Grant Support**

***Ongoing Research Support***

**Control of Peptide Hormone Biosynthesis by PC2 and 7B2**  09/15/96- 03/31/13

RO1 DK49703-16 I. Lindberg (P.I.)

NIH/NIDDK  $389, 264 current year total costs

This grant is to investigate the role of the neuroendocrine protein 7B2 in peptide hormone synthesis through cell biological approaches as well as mouse knockout experiments. Renewal application submitted Nov 2012.

**ARRA Supplement** received in 2010 for purchase of AKTA FPLC ($70,000)

**Opioid Peptide Synthesizing Enzymes**  04/01/88- 11/30/14

RO1 DA05084-24 I. Lindberg (P.I).

NIH/NIDA $396, 705 current year total costs

This grant is to identify regulatory mechanisms for PC1 activity; to identify small molecule convertase inhibitors using combinatorial compound screening; and to crystallize PC1.

**De-Orphanizing the Peptidome** 07/01/09-06/30/13

R01 DA027170-04 I. Lindberg and B. Roth (co-P.I.s)

NIH/NIDA $295,515 current year total costs

This grant is to identify novel ligand-receptor pairs through systematic screening of novel and known peptide products against novel orphan receptors.

***Pending Proposals***

**The Secretory Chaperone 7B2 as an Endogenous Regulator of Amyloid Pathology** 6/2012- 8/2012

R01 AGXXXX (under assignment)

NIH/NIA

This grant is to validate the role of 7B2 in plaque progression by performing cross-breeding of animals over- and under-expressing the 7B2 protein with a mouse model of Alzheimer’s disease.

**The competitive renewal of DK49703 is also under review at this time.**

***Completed Research Support (Competing applications of above grants and others)***

1/85 ‐ 12/86 I. Lindberg, PI

“Pharmacologic control of opioid peptide biosynthesis.”

  Pharmaceutical Manufacturer’s Association Starter Grant

4/85 ‐ 11/88   I. Lindberg, PI  (30% effort)

   “Biosynthesis of enkephalin in the adrenal medulla.”

R01 DK35199‐01

4/88 ‐ 3/91 I. Lindberg, PI (30% effort)

ʺOpioid peptide‐synthesizing enzymesʺ

R01 DA05084‐01

7/88 ‐ 6/93     I. Lindberg, PI (90% salary)

       Research Career Development Award

K04 DK01868  (salary award)

12/88 ‐ 11/91  I. Lindberg, PI    (30% effort)

    “Biosynthesis of enkephalin in the adrenal medulla.”

R01 DK35199‐04

4/91 ‐ 3/94   I. Lindberg, PI  (30% effort)

1. ʺOpioid peptide‐synthesizing enzymesʺ
2. R01 DA05084‐04

10/93‐ 9/98  I. Lindberg, PI (75% salary)

      Research Scientist Development Award

K02 DA00204‐01  (salary award)

4/94 ‐ 3/99  I. Lindberg, PI  (30% effort)

1. ʺOpioid peptide‐synthesizing enzymesʺ
2. R01 DA05084‐07

7/96‐ 3/02    I. Lindberg, PI   (30% effort)

1. “Control of peptide hormone biosynthesis by PC2 and 7B2”
2. R01 DK49703

10/98‐ 9/03    I. Lindberg, PI (75%)

      Research Scientist Development Award

K02 DA00204‐06  (salary award renewal)

4/99‐ 4/04 I. Lindberg, PI (30% effort)

  “Opioid peptide‐synthesizing enzymesʺ

R01 DA05084‐12

2004  I. Lindberg, PI Gordon Conference support grant

      “Proprotein processing, trafficking and secretion”

5R13DK061936‐04

2004 I. Lindberg, PI NSF Conference Support: received $2,000 for

a poster award program for the same Gordon Conference cited above

9/02‐8/05   I. Lindberg, PI) (20% effort)

       “Blockade of anthrax toxin cytotoxicity using furin inhibitors”

R21 AI 053517

8/03-8/06 P. Sunkara, PI (5% effort)

“Hexa-D-Arg: a furin inhibitor for anthrax biodefense”

Subcontract, Molecular Therapeutics

SBIR R43 A1056850

9/04-3/06 S. Pincus, PI (5% effort)

“Furin Inhibition in HIV Disease”

R21 AI058714

3/06‐6/06  I. Lindberg, PI (10% effort)

       “Furin as an Anti‐Cancer Target”

Louisiana Cancer Research Consortium

6/09-5/11 I. Lindberg, PI (20% effort)

“Identification of Novel Peptide Hormones”

R21 DK084481

Contributed sections to several **COBREs**and**equipment grants** awarded to  LSUHSC faculty; also contributed to various **ARRA Equipment Supplement/** **Multi-User** **Equipment** applications at the University of Maryland)

***Research Support as Mentor***

7/95‐6/98Mentor to Dr. Xiaorong Zhu, NRSA postdoctoral fellowship

10/97‐8/00 Mentor to Ms. Yolanda Fortenberry, NRSA predoctoral fellowship

12/06-12/07    Mentor to Dr. Wagner Judice, 1 year NIDA INVEST fellowship

08/10-present Mentor to Dr. Michael Helwig, Leopoldina fellowship

06/11-6/2012 Co-mentor to Dr. Laura Sanglas, Danish Academy fellowship 

**Patents**

1. Patent # 6,548,736 on the 7B2 null mouse as a model for pituitary Cushing’s was granted to C.H. Westphal, **I. Lindberg,** and P. Leder.

2. Patent # 7,033,991 on polyarginine furin inhibitors in inhibiting bacterial disease and cancer was granted on April 25, 2006 to **I. Lindberg**, A. Cameron, J. Appel, and R.A. Houghten.

**Publications**

***Peer-Reviewed Journals***

1. **Lindberg,** I., Smythe, S., and Dahl, J.L. (1979) Distribution of enkephalin in bovine brain. Brain Research, 168, 200-203.

2. **Lindberg, I.,** and Dahl, J.L. (1981) Characterization of enkephalin release from rat striatum. J. Neurochem. 36, 506-512.

3. Epstein, M., **Lindberg, I.,** and Dahl, J.L. (1981) Development of enkephalinergic neurons in the gut of the chick. Peptides 2, 271-276.

4. **Lindberg, I**., Yang, H.-Y.T., and Costa, E. (1982) An enkephalin-generating enzyme in bovine adrenal medulla. Biochem. Biophys. Res. Commun. 106, 186-1934.

5. Dahl, J.L., Epstein, M.L., Silva, B.W., and **Lindberg, I.** (1982) Multiple forms of met5- and leu5-enkephalin in fetal and neonatal rat brain and gut. Life Sci. 31, 1853-1856.

6. **Lindberg**, I., Yang, H.-Y.T., and Costa, E. (1982) Characterization of a partially purified trypsin-like enkephalin-generating enzyme in bovine adrenal medulla. Life Sci. 31, 1713-1716.

7. **Lindberg, I.,** Yang, H.-Y.T., and Costa, E. (1983) A high molecular weight form of met5-enk-arg6-gly7-leu8 in rat brain and bovine adrenal chromaffin granules. Life Sciences 33 Supp. I., 5-8.

8. **Lindberg, I.,** and Yang, H.-Y.T. (1984) Distribution of met5-enkephalin-arg6-gly7- leu8-immunoreactive peptides in rat brain: presence of multiple immunoreactive forms. Brain Research 299, 73-78.

9. **Lindberg, I.,** Yang, H.-Y.T., and Costa, E. (1984) Further characterization of an enkephalin-generating enzyme from bovine adrenal chromaffin granules. J. Neurochem. 42, 1411-1419.

10. **Lindberg, I**., Yang, H.-Y.T., and Costa, E. (1985) Release of multiple immunoreactive forms of met5-enkephalin-arg6-gly7-leu8 from rat brain. Neuropeptides 5, 541-544.

11. **Lindberg, I**., and White, L. (1986) Reptilian enkephalins: implications for the evolution of proenkephalin. Arch. Biochem. Biophys. 245, 1-7.

12. Wang, Y.N. and **Lindberg, I.** (1986) Distribution and characterization of met-enk-arg-gly-leu in the gastrointestinal tract of the rat. Cell and Tiss. Res. 244, 77- 85.

13. **Lindberg, I.,** and White, L. (1986) Distribution of immunoreactive Peptide B in the rat brain. Biochem. Biophys. Res. Commun. 139, 1024-1032.

14. **Lindberg, I.** (1986) Reserpine-induced alterations in the processing of proenkephalin in cultured chromaffin cells: increased amidation. J. Biol. Chem. 261, 16317- 16323.

15. Panula, P., and **Lindberg, I.** (1987) Pituitary enkephalins: biochemical and immunohistochemical observations. Endocrinology 121, 48-58.

16. Byrd, J., Naranjo, J., and **Lindberg, I.** (1987) Proenkephalin gene expression in the PC12 cell line: stimulation by sodium butyrate. Endocrinology 121, 1299-1305.

17. D'Souza, N. and **Lindberg, I.** (1988) Evidence for the phosphorylation of a proenkephalin-derived peptide, Peptide B. J. Biol. Chem. 263, 2548-2552.

18. Shen, F.S. and **Lindberg, I.** (1988) Characterization of enkephalin-immunoreactive peptides generated from plasma proteins by peptic digestion. Endocrinology 122, 2905-2910.

19. Shen, F-S., and **Lindberg, I.** (1989) Purification and assay of opioid activity of low molecular weight enkephalin-immunoreactive peptides generated by peptic digestion of rat plasma proteins. Neuropeptides 13, 23-28.

20. Shen, F.-S., Roberts, S.F., and **Lindberg, I.** (1989) A putative processing enzyme for proenkephalin in bovine adrenal chromaffin granules- purification and characterization. J. Biol. Chem. 264, 15600-15605 (1989).

21. **Lindberg, I**., and Thomas, G. (1990) Cleavage of proenkephalin by a chromaffin granule processing enzyme. Endocrinology 126, 480-487.

22. Irvine, J., Roberts, S.F., and **Lindberg, I.** (1990) Electrophoretic analysis of proteinases in sodium dodecyl sulfate polyacrylamide gels containing copolymerized radiolabelled protein substrates: application to proenkephalin processing enzymes. Analyt. Biochem.190, 141-146.

23. **Lindberg, I.,** Shaw, E., Finley J., Leone, D., and Deininger, P. (1991) Posttranslational modifications of recombinant rat proenkephalin overexpressed in Chinese hamster ovary cells. Endocrinology 128, 1849-1856.

24. Irvine, J.W., and **Lindberg, I.** (1991) Partial purification and characterization of a putative prohormone processing enzyme complex from bovine pituitary. Endocrinology, 128, 2345- 2352.

25. **Lindberg, I.,** and Shaw, E. (1992) Posttranslational processing of proenkephalin in a human neuroblastoma cell line, SK-N-MC. J. Neurochem. 58, 458-453.

26. Roberts, S.F., Irvine, J.W., and **Lindberg, I.** (1992) Proteolytic activity in bovine adrenal chromaffin granules visualized using [35S]methionine-labelled proenkephalin copolymerized into SDS-PAGE. J. Neurochem. 58, 593-599.

27. **Lindberg, I.,** Lincoln, B., and Rhodes, C.J. (1992) Fluorometric assay of a calcium-dependent, paired basic processing endopeptidase present in insulinoma granules. Biochem. Biophys. Res. Commun. 183, 1-7.

28. Vindrola, O., and **Lindberg, I.** (1992) Biosynthesis of the prohormone convertase mPC1 in AtT-20 cells. Mol. Endocrinol. 6, 1088-1094.

29. Mathis, J., and **Lindberg, I.** (1992) Posttranslational processing of proenkephalin in AtT-20 cells: evidence for cleavage at a Lys-Lys site. Endocrinology 131, 2287-2296*.*

30. Zhou, Y., and **Lindberg, I.** (1993) Purification and characterization of the prohormone convertase PC1 (PC3) J. Biol. Chem. 268, 5615- 5623.

31. Shen, F.S., Seidah, N.G., and **Lindberg, I.** (1993) Biosynthesis of the prohormone convertase PC2 in Chinese hamster ovary cells and in rat insulinoma cells. J. Biol. Chem. 268, 24910-24915.

32. Breslin, M., **Lindberg, I.**, Benjannet, S., Lazure, C., Mathis, J.P., and Seidah, N.G. (1993) Processing of proenkephalin by PC1(PC3), PC2, and furin. J. Biol. Chem. 268, 27084-27093.

33. Vindrola, O., and **Lindberg, I.** (1993) Release of the prohormone convertase PC1 from AtT-20 cells. Neuropeptides 25, 151-160.

34. Hornby, P.J., Rosenthal, S.D., Mathis, J.P., Vindrola, O., and **Lindberg, I.** (1993) Immunocytochemical analysis of the neuropeptide-synthesizing enzyme PC1 in AtT-20 cells. Neuroendocrinol. 58, 555-563.

35. Dupuy, A., **Lindberg,I.,** Zhou, Y., Akil, H., Lazure, C., Chretien, M., Seidah, N.G., and Day, R. (1994) Processing of prodynorphin by the prohormone convertase PC1 results in high molecular weight intermediate forms: cleavage at a single arginine. FEBS Lett. 337:60-65*.*

36. O'Hara, B.F., Donovan, D., **Lindberg, I.**, Brannock, M.T., Ricker, D.D., Moffatt, C.A., Klaunberg, B.A., Schindler, C., Chang, T.S.K., Nelson, R.J., and Uhl, G.R. (1994) Proenkephalin transgenic mice: a short promotor confers high testis expression and reduced fertility. Mol. Reprod. and Devel. 38, 275-284.

37. Martens, G.M., Braks, A.M., Eib, D., Zhou, Y., and **Lindberg, I.** (1994) The neuroendocrine polypeptide 7B2 is a naturally occurring inhibitor of the prohormone convertase PC2. Proc. Nat. Acad. Sci. 91, 5784-5785.

38. **Lindberg, I.** (1994) Evidence for cleavage of the PC1/PC3 prosegment in the endoplasmic reticulum. Mol. Cell. Neurosci. 5*,* 263-268*.*

39. Zhou, Y., and **Lindberg, I.** (1994) Enzymatic properties of carboxy-terminally truncated prohormone convertase 1 (PC1/PC3). J. Biol. Chem. 269, 18408-18413.

40. **Lindberg, I.**, Ahn, S.C. and Breslin, M.B. (1994) Cellular distributions of the prohormone processing enzymes PC1 and PC2. Mol. Cell. Neurosci.5, 614-622.

41. **Lindberg, I.**, Van den Hurk, W.H., Bui, C.B., and Batie, C.J. (1995) Enzymatic characterization of immunopurified prohormone convertase PC2: potent inhibition by a 7B2 peptide fragment.Biochemistry34, 5486- 5493.

42. Rothenberg, M.E., Eilertson, C.D., Klein, K., Zhou, Y., **Lindberg, I.**, McDonald, J.K., and Noe, B.D. (1995) Processing of mouse proglucagon by recombinant PC1 and PC2*.* J. Biol. Chem.270, 10136-10146.

43. Van Horssen, A. M., Van den Hurk, H., Bailyes, E.M., Hutton, J.C., Martens, G.J.M., and **Lindberg, I.** (1995) Identification of the region within the neuroendocrine polypeptide 7B2 responsible for the inhibition of prohormone convertase 2.J. Biol. Chem. 270, 14292-14296.

44. Zhu, X., and **Lindberg, I.** (1995) 7B2 facilitates the maturation of proPC2 in neuroendocrine cells and is required for the expression of enzymatic activity. J. Cell Biol. 129, 1641-1650.

45. Zhou, Y., Rovere, C., Kitabgi, P., and **Lindberg, I.** (1995) Mutational analysis of PC1 in PC12 cells: 66 kDa PC1 is fully functional. J. Biol. Chem.270, 24702-24706.

46. Johanning, K., Mathis, J.P., and **Lindberg, I.** (1996) Role of the prohormone convertase PC2 in proenkephalin processing: antisense and overexpression studies. J. Neurochem. 66, 898-907.

47. Zhu, X., Rouille, Y., Lamango, N. S., Steiner, D. F., and **Lindberg, I.** (1996) Internal cleavage of the PC2 inhibitor 7B2 CT peptide: a potential inactivation mechanism. Proc. Natl. Acad.Sci. 93, 4919-4924.

48. Lamango, N., Zhu, X., and **Lindberg, I.** (1996) Purification and enzymatic characterization of recombinant PC2: stimulation of activity by 21 kDa 7B2. Arch. Biochem. Biophysics330, 238-250.

49. Zhu, X., Lamango, N.S., and **Lindberg, I.** (1996) Involvement of a polyproline helix-like structure in the interaction of 7B2 with prohormone convertase 2. J. Biol. Chem. 271, 23582-23587.

50. Johanning, K., Mathis, J.P., and **Lindberg, I.** (1996) Processing site blockade results in more efficient conversion of proenkephalin to active opioid peptides. J. Biol. Chem. 271, 27871-27878.

51. Muller, L., Zhu, X., and **Lindberg, I.** (1997) Mechanism of facilitation of PC2 maturation by 7B2: involvement in PC2 transport and activation, but not folding. J. Cell. Biol. 139, 625-638.

52. Zhu, X., Muller, L., Mains, R.E. and **Lindberg, I.** (1998) Structural elements of PC2 required for its interaction with its helper protein 7B2. J. Biol. Chem. 273, 829-836.

53. Day, R., Lazure, C., Basak, A. Boudreault, A., Limperis, P., Dong, W., and **Lindberg I.** (1998) Prodynorphin processing by proprotein convertase 2 (PC2): cleavage at single basic residues and enhanced processing in the presence of carboxypeptidase. J. Biol. Chem. 273, 1153- 1164.

54. **Lindberg, I.**, Tu, B., Muller, L., and Dickerson, I. (1998) Cloning and functional analysis of *C. elegans* 7B2. DNA and Cell Biol. 17, 727-734.

55. Apletalina, E., Appel, J., Lamango, N.S., Houghten, R., and **Lindberg, I.** (1998) Identification of potent inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library. J. Biol. Chem. 273, 26589-26595.

56. Johanning, K., Juliano, M.A., Juliano, L., Lazure, C., Lamango, N., Steiner, D.F., and **Lindberg, I.** (1998) Specificity of prohormone convertase 2 on proenkephalin and proenkephalin-related fluorogenic peptides. J. Biol. Chem. 273, 22672-22680.

57. Lamango, N.S., Apletalina, E., Liu, J., and **Lindberg, I.** (1999) Conversion of proPC2 is a pH-driven process. Arch. Biochem. Biophys. 362, 275-282.

58. Westphal, C.H., Muller, L., Zhou, A., Zhu, X., , Bonner-Fraser, S., Schambelan, M., Steiner, D.F., **Lindberg, I.**\*, Leder, P.\* (1999) The neuroendocrine protein 7B2 is required for peptide hormone processing *in vivo* and provides a novel mechanism for pituitary Cushing’s disease. Cell 96, 689-700. (\*co-senior authors)

59. Muller, L., Zhu, P. Juliano, M.A., Juliano, L., and **Lindberg, I.** (1999) A 36-residue peptide contains all of the information required for 7B2-mediated activation of proPC2. J. Biol. Chem., 274, 21471-21477.

60. Fortenberry, Y., Liu, J., and **Lindberg, I.** (1999) The role of the CT peptide in the inhibition of PC2 *in vivo*.J. Neurochemistry*,* 73, 994-1003*.*

61. Apletalina, E., Juliano, M. A., Juliano, L. and **Lindberg, I.**(2000) Structure-function analysis of the 7B2 CT peptide: mechanism of inhibition of PC2. Biochem. Biophys. Res. Commun. 267, 940-942.

62. Apletalina, E., Muller, L., and **Lindberg, I.** (2000) Mutations in the catalytic domain of prohormone convertase 2 result in loss of binding to 7B2 and inhibition with 7B2 CT peptide. J. Biol. Chem., 275, 14667-14677.

63. Hwang, J.R., Siekhaus, D., Fuller, R.S., Taghert, P., and **Lindberg, I.** (2000) Characterization of prohormone convertase 2 and 7B2 from *Drosophila melanogaster.* J. Biol. Chem. 275, 17886-17893.

64. Cameron, A., Fortenberry, Y., and **Lindberg, I.** (2000) The SAAS granin exhibits functional homology to 7B2 and contains a highly potent hexapeptide inhibitor against PC1.FEBS Lett. 473, 135-138.

65. Cameron, A., Appel, J., Houghten, R.A. and **Lindberg, I.** (2000) Polyarginines are potent furin inhibitors. J. Biol. Chem. 75, 36741-36749.

66. Muller, L.\*, Cameron, A.\*, Apletalina, E. , Fortenberry, Y. and **Lindberg, I.** (2000) Processing and sorting of the prohormone convertase 2 propeptide. J. Biol. Chem.,275, 39213- 39222*..* (\*these authors contributed equally to the work)

67. Sayah, M., Fortenberry, Y., Cameron, A., and **Lindberg, I.** (2001) Distribution and enzymatic generation of proSAAS-derived peptides. J. Neurochem.  76*,* 1833-1841.

68. Hwang, J.R, and **Lindberg, I.** (2001) Inactivation of the 7B2 inhibitory CT peptide depends on a functional furin cleavage site. J. Neurochem. 79, 437-44.

69. Zachariah, C., Cameron, A., **Lindberg, I.**, Kao, K.J., Beinfeld, M., and Edison, A. (2001) Structural studies of a neuropeptide precursor protein with an RGD proteolytic site. Biochemistry 40, 8790-8799.

70. Rehfeld, J.F., **Lindberg, I.**, Friis-Hansen, L. (2002) Progastrin-derived peptides differ in 7B2 and PC2 knockout animals: a role for 7B2 independent of action on PC2. FEBS Lett. 510, pp. 89-93*82.*

71. Fortenberry, Y., Hwang, J.R., Apletalina, E.V., **Lindberg, I.** (2002) Functional characterization of proSAAS: similarities and differences with 7B2. J. Biol. Chem*.* 277, 5175-5186.

72. Sarac, M., Windeatt, S., Castro, M., and **Lindberg, I.** (2002) Adenoviral administration of 7B2 reverses endocrinological deficiencies in 7B2 null mice. Endocrinology 143, 2314-23.

73.Sarac, M., Zieske, A.W., and **Lindberg, I.** (2002). The lethal form of Cushing’s in 7B2 null mice is due to multiple metabolic and hormonal abnormalities. Endocrinology,143, 2324-32.

74. Laurent, V., Kimble, A., Peng, B., Zhu, P., Pintar, J., Steiner, D.F. and **Lindberg, I.** (2002) Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion. Proc. Natl. Acad. Sci. USA 99, 3087.

75. Zhu, X., Zhou, A., Dey, A., Norrbom, C., Carroll, R., Zhang C., Laurent V., **Lindberg, I.**, Ugleholdt, R., Holst, J.J., Steiner, D.F. (2002) Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc. Natl. Acad. Sci. USA 99, 10293-10298.

76. Laurent, V., and **Lindberg, I.** (2002) Mini-RIA: adaptation of conventional [125I] radioimmunoassay to a 96-tube format. Analytical Biochemistry309, 143-149.

77. Sarac, M.S., Cameron, A., **Lindberg, I.** (2002) The furin inhibitor hexa- D-arginine blocks the activation of *Pseudomonas aeruginosa* exotoxin A *in vivo*. Infection and Immunity70, 7136-7139.

78. Laslop, A., Becker, A., **Lindberg, I.**, Fischer-Colbrie, R. (2002) Proteolytic processing of chromogranins is modified in brains of transgenic mice. Ann N. Y. Acad Sci. 971,49-52.

79. Li, Q.L., Naqvi, L., **Lindberg, I.** and Friedman, T.C. (2003) Prohormone convertase 2 (PC2) enzymatic activity and its regulation in endocrine cells. Regul. Pept. 110,197-205.

80. Rehfeld, J.F., **Lindberg, I.** and Friis-Hansen, L. (2003) Increased synthesis but decreased processing of neuronal proCCK in PC2 and 7B2 knockout animals. J. Neurochem. 83, 1329-37.

81. Cornwall,G.A, Cameron, A., **Lindberg, I.**, Hardy, D.M., and Hsia, N. (2003) CRES inhibits the serine protease prohormone convertase 2. Endocrinology144, 901-8.

82. Henrich, S., Cameron, A., Bourenkov, G.P., Kiefersauer, R., Huber, R., **Lindberg, I.,** Bode, W., and Than, M.E. (2003) The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nature Structural Biology 10, 520-526.

83. Peinado, J.R., Li, H., Johanning, K., and **Lindberg, I.**(2003) Cleavage of recombinant proenkephalin and blockade mutants by prohormone convertases 1 and 2: an *in vitro* specificity study. J. Neurochem. 87, 868-78.

84. Winsky-Sommerer, R., Grouselle, D., Rougeot, C., Laurent, V., David, J.P., Delacourte, A., Dournaud, P., Seidah, N.G., **Lindberg, I.,** Trottier, S., and Epelbaum, J. (2003) The proprotein convertase PC2 is involved in the maturation of prosomatostatin to somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease. Neuroscience 122, 437-47.

85. Laurent, V., Jaubert-Miazza, L., Desjardins, R., Day, R., and **Lindberg, I.**(2004) Biosynthesis of POMC-derived peptides in prohormone convertase 2 and 7B2 null mice. Endocrinology, 145, 519-28.

86. Sarac, M.S., Peinado, J.R., Leppla, S.H., and **Lindberg, I**. (2004) Protection against anthrax toxemia by hexa-D-arginine *in vitro* and *in vivo*. Infection and Immunity72, 602-605.

87. Kacprzak, M., Peinado, J.R., Than, M., Appel,J., Henrich, S., Bode, W., Houghten, R.A., and **Lindberg, I.** (2004) Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J. Biol. Chem.279, 36788-94

88. L**e**e S.N., Prodhomme, E., **Lindberg, I.** (2004) Prohormone convertase 1 (PC1) processing and sorting: effect of PC1 propeptide and proSAAS. J. Endocrinol. 182, 353-364.

89. Peinado, J.R., Kacprzak,M., Leppla,S.H. and **Lindberg, I.** (2004) Cross-inhibition between furin and lethal factor inhibitors. FEBS Lett.321, 601-605.

90. Henrich, S. **Lindberg, I.**, Bode,W., and Than, M.E. (2004) Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J. Biomol. Structure 345, 211-27.

91. Peinado, J.R.\*, Laurent, V.\*, Lee, S.N., Peng, B.W., Pintar, J.E., Steiner, D.F. and **Lindberg, I.** (2005)Strain-dependent influences on the hypothalamo-pituitary-adrenal axis profoundly affect the 7B2 null phenotype**.** *(\*co-first authors)*  Endocrinology 146, 3438-44.

92. Kacprzak, M.M., Than, M.E, Juliano, L., Juliano, M.A., Bode, W., and **Lindberg. I.** (2005) Mutagenesis of the PC2 substrate binding pocket alters enzyme specificity. J. Biol. Chem. 280, 31850-8.

93. [Shiryaev, S.A](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Shiryaev+SA%22%5BAuthor%5D), [Ratnikov, B.I](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Ratnikov+BI%22%5BAuthor%5D), [Chekanov, A.V](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Chekanov+AV%22%5BAuthor%5D)., [Sikora, S](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Sikora+S%22%5BAuthor%5D)., [Rozanov, D.V](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Rozanov+DV%22%5BAuthor%5D)., [Godzik, A](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Godzik+A%22%5BAuthor%5D)., [Wang, J](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Wang+J%22%5BAuthor%5D)., [Smith, J.W](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Smith+JW%22%5BAuthor%5D)., [Huang, Z](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Huang+Z%22%5BAuthor%5D)., [**Lindberg, I**](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Lindberg+I%22%5BAuthor%5D)**.,** [Samuel, M.A](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Samuel+MA%22%5BAuthor%5D)., [Diamond, M.S](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Diamond+MS%22%5BAuthor%5D)., [Strongin, A.Y](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Strongin+AY%22%5BAuthor%5D). (2005) The cleavage targets and the (D)-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochemistry393, 503-11.

94. **Lindberg, I.** (2005) Balancing risk and recovery. Science 310, 972.

95. Lee, S.N., Hwang, J.R., and **Lindberg, I.** (2006) The neuroendocrine protein 7B2 can be inactivated by phosphorylation within the secretory pathway. J. Biol. Chem. 281, 3312-20.

96. Ozawa A., Cai, Y., and **Lindberg I.** (2007) Production of bioactive peptides in an *in vitro* system. Analytical Biochem. 366:182-9.

97. Lee, S.N., Peng, B., Desjardins, R., Pintar, J.E., Day, R., and **Lindberg, I.** (2007) Strain-specific steroidal control of pituitary function. J. Endocrinol. 192: 515-25.

98. Fugere, M., Appel, J., Houghten, R.A., **Lindberg, I.,** and Day, R. (2007) Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: use of PS-SPCL as a tool for the optimization of inhibitory sequences. Molecular Pharmacology 71, 323-332.

99. Lee, S.N., Kacprzak, M.M., Day, R., and **Lindberg I.** (2007) Processing and trafficking of a prohormone convertase 2 active site mutant. Biochem Biophys Res Commun. 355, 825-9.

100. Waha, A., Koch, A., Hartmann, W., Milde, U., Felsberg, J., Hübner, A., Mikeska, T., Goodyer, C.G., Sörensen, N., **Lindberg, I.,** Wiestler, O.D., Pietsch, T, Waha, A. (2007) SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas. Oncogene 26: 5662-8.

101. Lee, S.N. and **Lindberg, I.** (2008) 7B2 prevents unfolding and aggregation of prohormone convertase 2. Endocrinology 149: 4116-27.

102. Farber, C.R., Chitwood, J. Lee, S.N., Verdugo, R., Islas-Trejo, Rincon, A.G., **Lindberg, I.** and Medrano, J.F. (2008) Overexpression of Scg5 increases enzymatic activity of PCSK2 and is negatively correlated with weight gain in congenic mouse models. BMC Genet. 9:34 .

103. Kudo, H., Liu, J., Roubos, E., Ozawa, A., Panula, P. Martens, G.J.M., and **Lindberg, I.** (2009) Identification of proSAAS homologs in lower vertebrates: conservation of hydrophobic helices and convertase-inhibiting sequences. Endocrinology 150:1393-9.

104. Kowalska, D., Liu, J., Appel, J.R., Ozawa, A., Nefzi, A., Mackin, R.B., Houghten, R.A., and **Lindberg, I.** (2009) Synthetic small molecule prohormone convertase 2 inhibitors. Molecular Pharmacology 75: 617-25.

105. Ozawa, A., Speaker, R.B., and **Lindberg, I.** (2009) Enzymatic characterization of an HEL cell acyltransferase activity PLoS One 4(5):e5426.

106. Izidoro, M.A., Gouvea, I.E., Santos, J.A., Assis, D.M., Oliveira, V., Judice, W.A., Juliano, M.A., **Lindberg, I.,** and Juliano, L. (2009) A study of human furin specificity using synthetic peptides derived from natural substrates: effects of potassium ions. Arch. Biochem. Biophys. 487:105-14.

107. Becker, G.L, Sielaff, F., Than, M.E., **Lindberg I.,** Routhier, S., Day, R., Lu, Y., Garten, W., and Steinmetzer,T. (2009) Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J. Med Chem. 53: 1067-75.

108. Izidoro, M.A., Assis, D.A., Oliveira, V., Santos, J.A.N, Juliano, M.A., **Lindberg, I.,** and Juliano, L. (2010) Effect of magnesium ions on recombinant human furin: selective activation of hydrolysis of substrates derived from virus envelope glycoproteins. Biol. Chem. 391: 1105-12.

109. Ozawa, A., Peinado, J.R., and **Lindberg, I.** (2010) Modulation of prohormone convertase 1/3 properties using site-directed mutagenesis.  Endocrinology 151: 4437-45.

110. Hoshino, A., Kowalska, D., Jean, F., Lazure, C., and **Lindberg, I.** (2011) Modulation of PC1/3 activity by self-interaction and substrate binding. Endocrinology, 152:1402-11

111. Sielaff, F., Than, M.E., Bevec, D., **Lindberg, I.,** and Steinmetzer, T. (2011) New furin inhibitors based on weakly basic amidinohydrazones. Bioorg. Med. Chem. Lett. 21: 836-40.

112. Ozawa, A. Lick, A, and **Lindberg, I.** (2011) Processing of augurin is required to suppress proliferation of tumor cell lines. Mol. Endocrinol. 25:776-84. PMID: 21436262

113. Helwig, M., Vivoli, M., Fricker, L.D., and **Lindberg I.** (2011) Regulation of neuropeptide processing enzymes by catecholamines in endocrine cells. Mol. Pharmacol. 80:304-13. PMID: 21540292

114. Helwig, M., Lee, S-N.L, Hwang, J.R., Ozawa, A., Medrano, J.F., and Lindberg, I. (2011) Dynamic modulation of PC2-mediated precursor processing by 7B2. J. Biol. Chem. 286:42504-13. PMID: 22013069

115. Kuester, M., Becker, G.L., Hardes, K., **Lindberg, I.,** Steinmetzer, T., Than, M.E. (2011) Purification of the proprotein convertase furin by affinity chromatography based on PC-specific inhibitors. Biol Chem. 392: 973-81.

116. Toll, L., Khroyan, T.V., Sonmez, K., Ozawa, A., **Lindberg, I.,** McLaughlin, J.P, Eans, S.O., Shahien, A.A, and Kapusta, D.R. (2012) Peptides derived from the prohormone proNPQ/Spexin are potent central modulators of cardiovascular and renal function and nociception. FASEB J. 26(2):947-54. Epub 2011 Oct 28. PMID: 22038051

117. Vivoli, M., Caulfield, T.R., Martínez-Mayorga, K., Johnson, A.T., Jiao, G.-S. and **Lindberg,** **I**. (2012) Inhibition of PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives. Mol. Pharmacol.  81(3):440-54. Epub 2011 Dec 14*.* PMID: 22169851

118. Becker, G.L., Lu Y., Hardes, K., Strehlow, B., Levesque, C., **Lindberg, I.,** Sandvig, K., Bakowsky, U., Day, R., Garten, W., Steinmetzer ,T. (2012) Highly potent inhibitors of the proprotein convertase furin as potential drugs for the treatment of infectious diseases. J. Biol. Chem. 287(26):21992-2003

119. Yuan B., Feng J.Q., Bowman, S., Ying, L., Blank, R.D., **Lindberg, I.,** and Drezner, M.K. (2012) Hexa-D-Arginine treatment increases 7B2-PC2 activity in hyp mouse osteoblasts and rescues the hyp phenotype. J. Bone and Mineral Res 28(1):56-72.

120. Dasgupta, I.\*, Sanglas, L.\*, Enghild, J. and **Lindberg I.** (2012) The neuroendocrine protein 7B2 is an intrinsically disordered protein. Biochemistry, *in press.* (co-first authors)

121. Zhu, J., Declercq, J., Roucourt, B., Ghassabeh, G.H., Meulemans, S., Kinne, J., David, G., Vermorken, A.J., Van de Ven, W.J., Lindberg, I., Muyldermans, S., and Creemers, J.W. (2012) Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochem J.  448(1):73-82. PMID: 22920187

122. Pickett, LA, Yourshaw, M., Chen, Z. Solorzano-Vargas, RS, Nelson, SF, Martín, MG, and **Lindberg, I**. (2012) Secretion and maturation of novel variants of *PCSK1*. PLoS One, *in press.*

123. Helwig, M., Hoshino, A., Berridge, C., Lee, S.N., Lorenzen, N., Otzen, D., Eriksen, J., and **Lindberg, I**. (2012) The neuroendocrine protein 7B2 suppresses neurodegenerative disease-related protein aggregation. J. Biol. Chem.  *in press.*

***Reviews***

1. **Lindberg, I.** On the evolution of proenkephalin. (1986) Trends in Pharmacol. Sci. 7, 216-218.

2. **Lindberg, I.,** and Hutton, J. C. (1991) “Peptide processing proteinases with selectivity for paired basic amino acids” *in* The Biosynthesis of Peptide Hormones and Neurotransmitters (L.D. Fricker, Ed.) CRC Press, Boca Raton, Fl.

3. **Lindberg, I.** (1991) The new mammalian precursor processing proteinases. Mol. Endocrinol. 5, 1361-1365.

4. **Lindberg, I**. and Zhou, Y. (1995) “Overexpression of neuropeptide precursors and processing enzymes” in "Peptidases and neuropeptide processing. *in* Methods in Neuroscience, Vol 23, 94-108. (A. Ian Smith, Ed.) Academic Press, Orlando, FL

5. **Lindberg, I.** (1996) “Polypeptide hormones: biosynthesis, processing, and secretion” *in* The Encyclopedia of Molecular Biology, VCH Press, Weinheim, Germany (R.A. Myers, Ed.)

6. Creemers, J.M.W., Bailyes, E.M., **Lindberg, I.**, and Hutton, J.C. (1999) “Proteolytic Processing” *in*  Protein Expression- A Practical Approach (Eds. B.D. Hames and S.J. Higgins) Oxford University Press, Oxford, UK.

7. Muller, L., and **Lindberg, I.** (1999) “The cell biology of the prohormone convertases PC1 and PC2.” *in* Progress in Nucleic Acids Research (K. Moldave, Ed.) Academic Press, San Diego, CA pp69-108

8. Murray, S., Coste, S., **Lindberg, I.** and Stenzel-Poore, M. (2001) “Genetic mutants with dysregulation of corticotropin pathways.” *in* Transgenic Models in Endocrinology (M. Castro, Ed.)

9. Cameron, A., Apletalina, E. and **Lindberg, I.** (2001) The enzymology of prohormone convertases PC1 and PC2. *in* The Enzymes (R.E. Dalbey, Ed). Academic Press, San Diego, CA

10. Ozawa, A., **Lindberg, I**., Roth, B.A., and Kroeze, W. (2010) Deorphanization of novel peptides and their receptors. AAPS J. 12:378-84.

11. **Lindberg, I.** and Appel, J. (2011) “Inhibitor screening of proprotein convertases using positional scanning libraries” *in* Methods in Molecular Biology #768: Proprotein Convertases (M. Mbikay, Ed). Springer Protocols,768:155-66. PMID: 21805241

12. M. Vivoli and **Lindberg, I.** (2012) “Prohormone convertase 1/3”: *in* Handbook of Biologically Active Peptides. (A. Kastin, Ed). Academic Press. *In press.*

13. M. Vivoli, M. and **Lindberg, I.** (2012) “Prohormone convertase 2”: *in* Handbook of Biologically Active Peptides. (A. Kastin, Ed). Academic Press. *In press.*

14. Hoshino A., and **Lindberg, I.** (2012) The biochemistry and cell biology of prohormone convertases 1/3 and 2. *in* Neuropeptide Biosynthesis (E-Book) (L. Devi and L.D. Fricker, Eds). Morgan and Claypool Life Sciences Publishers.

***Book Chapters (Meeting Proceedings)***

1. Epstein, M., Dahl, J.L., and **Lindberg, I.** (1982) Ontogeny of leu- and met-enkephalin in chick brain; an enkephalin-like substance present in embryonic, but not adult brain. In: Rich, D., and Gross, E. (Eds.) Proceedings of the Seventh American Peptide Symposium. Rockford, Illinois, Pierce Chemical Co., pp 633-636.

2. **Lindberg, I.,** Yang, H.-Y.T., and Costa, E. (1982) Enzymatic production of met5-and leu5-enkephalin in adrenal chromaffin granules. in: Adv. Biochem. Psychopharmacol. 33, 183-191 (M. Trabucchi and E. Costa, Eds)

3. **Lindberg, I.,** and Yang, H.-Y.T. (1983) A met5 - and leu5-enkephalin-generating enzyme in bovine adrenal medulla. In: Hanin,I .(Ed.) Dynamics of Neurotransmitter Function. New York, Raven Press.

4. **Lindberg, I**. (1987) The chromaffin granule trypsin-like protease- a kallikrein? In Proteases in Biological Control and Biotechnology (Eds: D.D. Cunningham & G. Long) pp. 269-275.

5. Shen, F.-S. and **Lindberg, I.** (1989) Salt inhibition of the adrenal trypsin-like enzyme. In Adv. in Biosciences 75, 237-240. Pergamon Press (M. Hamon, Ed.)

**Recent Invited Presentations**

***Title of most presentations:******“Proprotein convertases and their inhibitors”***

*December 2005*Burnham Institute, San Diego, CA

*January 2006*University of Arizona, College of Medicine, Phoenix, AZ

*March 2006*University of Georgia, Dept. of Biochemistry, Athens, GA

*April 2006*California Pacific Medical Center Research Institute, San Francisco, CA

*May 2006*Georgetown University, Department of Endocrinology, Washington DC

*August 2006*Temple University, Department of Biochemistry, Philadelphia, PA

*November 2006*University of Pittsburgh, Department of Pharmacology, PA

*December 2006* Boston University, Department of Pharmacology, Boston, MA

*December 2006* University of Maryland, Department of Anatomy and Neurobiology, Baltimore, MD

*February 2007* University of Maryland BioPark, Baltimore, MD

*April 2008* Johns Hopkins University, Dept. Endocrinology, Baltimore, MD

*July 2008* Gordon Conference, Proprotein Synthesis, Trafficking, and Secretion (NH)

*March 2009* Katholische Universitaet Leuven, Belgium

*December 2009* NIH, Bethesda, MD

*January 2011* American University,Washington DC

*January 2012* Department of Pharmacology, Temple University, Philadelphia, PA

*May 2012* Department of Biochemistry, Medical University of South Carolina, Charleston SC

*July 2012* Gordon Conference, Proprotein Synthesis, Trafficking, and Secretion (NH)

*August 2012* Regulatory Peptides Conference, Copenhagen, Denmark

*November 2012* Krasnow Institute, George Mason University, VA

**Research Interests**

My research focuses on the molecular entities within the secretory pathway required for the successful production of bioactive peptide hormones and neuropeptides from precursor proteins. These molecules include chaperones; abundant secretory proteins such as granins; and precursor processing enzymes- in particular, the proprotein convertases furin, PC1 and PC2. We study how these convertases are regulated within the cell; we are attempting their crystallization; and we are working on identifying activators and inhibitors through various pharmacological collaborations. Two new projects focus on novel neuronal chaperone proteins and the bone hormone FGF23. Lastly, a separate project focuses on the identification and functional analysis of novel peptide signaling molecules by exploitation of convertase cleavage sites. The widespread involvement of proprotein convertases in a variety of physiological processes means our work is directly linked to diseases such as Alzheimer’s; obesity; pain; diabetes; cancer; and bone disease.